A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Latest Information Update: 29 Oct 2021
At a glance
- Drugs Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 15 Jan 2021 Status changed from active, no longer recruiting to discontinued as manufacturer changed focus to cell therapy.
- 28 May 2020 Planned End Date changed from 30 Nov 2023 to 26 Feb 2021.
- 28 May 2020 Status changed from suspended to active, no longer recruiting.